Understanding symptoms and signs in inflammatory bowel disease

Inflammatory Bowel Disease: From Bench to Bedside

Volumn , Issue , 2006, Pages 253-267

  Cronin, Cornelius C ^a   Shanahan, Fergus ^b  

^a Mallow General Hospital   (Ireland)

^b Department of Medicine National University of Ireland Cork   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891402053     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-25808-6_13     Document Type: Chapter

References (70)

1. Munkholm P, Langholz E, Davidsen M, Binder V. Disease activity courses in a regional cohort of crohn's disease patients. Scand J Gastroenterol 1995; 30: 699-706
2. Curfs JH, Meis JF, Hoogkamf-Korstanje JA. A primer on cytokines: Sources, receptors, effects and inducers. Clin Microbiol Rev 1997; 10: 742-80
3. Lucey DR, Clerici M, Shearer GM. Type 1 and type 2 cytokine dysregulation in human infectious, neoplastic and inflammatory diseases. Clin Microbiol Rev 1996; 9: 532-62
4. Rivest S, Lacroix S, Vallieres L, Nadeau S, Zhang J, Laflamme N. How the blood talks to the brain parenchyma and the paraventricular nucleus of the hypothalamus during systemic inflammatory and infectious stimuli. Proc Soc Exp Biol Med 2000; 223: 22-38
5. Faggioni R, Benigni F, Ghezzi P. Proinflammatory cytokines as pathogenetic mediators in the central nervous system: Brain-periphery connections. Neuroimmunomodulation 1995;2:2-15
6. Slifka MK, Whitton JL. Clinical implications of dysregulated cytokine production. J Mol Med 2000; 78: 74-80
7. Kotler DR Cachexia. Ann Intern Med 2000; 133: 622-34
8. Engel GL. The need for a new medical model: A challenge for biomedicine. Science 1977; 196: 129-46
9. Drossman DA. Psychosocial factors in gastrointestinal disorders. In: Feldman M, Scharschmidt BF, Sleisenger MH, eds. Gastrointestinal and Liver Disease, 6th ed. Philadelphia: W.B. Saunders, 1998: 69-79
10. Klein KB. Approach to the patient with abdominal pain. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of Gastroenterology. Philadelphia: J.B. Lippincott, 1995:750-71
11. Ccrvero F, Laird JM. Visceral pain. Lancet 1999; 353: 2145-8
12. Bucno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: From basic to clinical implications. Gastroenterology 1997; 112: 1714-43
13. Bueno L, Fioramonti J, Garcia-Villar R. Pathobiology of visceral pain: Molecular mechanisms and therapeutic implications HI visceral afferent pathways: A source of new therapeutic targets for abdominal pain. Am J Physiol Gastrointest Liver Physiol 2000; 278: G670-6
14. Stokes MA. crohn's disease and nutrition. Br J Surg 1992; 79: 391-4
15. O'Keefc SJD, Rosser BG. Nutrition and inflammatory bowel disease. In: Targan SR, Shanahan F, eds. Inflammatory Bowel Disease: From Bench to Bedside. Baltimore: Williams&Wilkins, 1994:461-77
16. Rigaud D, Angel LA, Cerf M et al. Mechanisms of decreased food intake during weight loss in adult crohn's disease patients without obvious malabsorption. Am J Clin Nutr 1994; 60: 775-81
17. Kirschncr BS, Klich JR, Kalman SS. Reversal of growth retardation in crohn's disease with therapy emphasizing oral nutritional restitution. Gastroenterology 1981; 80: 10-15
18. Kelts DG, Grand RJ, Shen G, Watkins JB, Werlin SL, Boehme C. Nutritional basis of growth failure in children and adolescents with crohn's disease. Gastroenterology 1979; 76: 720-7
19. Aiges H, Markowitz J, Rosa J, Daum F. Home nocturnal supplemental nasogastric feedings in growth-retarded adolescents with crohn's disease. Gastroenterology 1989; 97: 905-10
20. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of crohn's disease. Gastroenterology 1988; 95: 1523-7
21. Lawrence CB, Turnbull AV, Rothwell NJ. Hypothalamic control of feeding. Curr Opin Neurobiol 1999; 9: 778-83
22. Stubbs RJ. Peripheral signals affecting food intake. Nutrition 1999; 15:614-25
23. Woods SC, Seeley RJ, Porte D, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science 1998; 280:1378-83
24. Bray GA. Afferent signals regulating food intake. Proc Nutr Soc 2000; 59:373-84
25. Inui A. Neuropeptide Y: A key molecule in anorexia and cachexia in wasting disorders. Mol Med Today 1999; 5: 79-85
26. Curzon G. Serotonin and appetite. Ann NY Acad Sci 1990; 600: 521-30
27. Halford JC, Blundell JE. Pharmacology of appetite suppression. Prog Drug Res 2000; 54: 25-58
28. Lieverse RJ, Jansen JBMJ, Masclee AAM, Lamers CBHW. Satiety effects of cholecystokinin in humans. Gastroenterology 1994;106:1451-4
29. Ballinger A, McLoughlin L, Medbak S, Clark M. Cholecystokinin is a satiety hormone in humans at physiological post-prandial plasma concentrations. Clin Sci (Colch) 1995;89:375-81
30. Kennedy GC. The role of depot fat in the hypothalamic control of food intake in the rat. Proc R Soc Lond 1953; 140: 578-92
31. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature 1998; 395: 763-70
32. Zhang Y, Proenca R, Maffel M, Barone M, Leopold L, Friedman J. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 372: 425-32
33. Fruhbeck G, Jebb SA, Prentice AM. Leptin: Physiology and pathophysiology. Clin Physiol 1998; 18: 399-419
34. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides mediation of the actions of leptin. Trends Neurosci 1999; 22: 62-7
35. Ballinger A, Farthing M. Intestinal disease, feeding behaviour and leptin role of the gut-brain axis. CNS 1999; 2: 12-16
36. Halford JC, Blundell JE. Separate systems for serotonin and leptin in appetite control. Ann Med 2000; 32: 222-32
37. Plata-Salaman CR. Cytokine-induced anorexia: Behavioral, cellular and molecular mechanisms. Ann NY Acad Sci 1998;856:160-70
38. Langhans W, Hrupka B. Interlcukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999; 33: 415-24
39. Daun JM, McCarthy DO. The role of cholecystokinin in interleukin-l induced anorexia. Physiol Behav 1993; 54: 237-41
40. Finck BN, Kclley KW, Dantzcr R, Johnson RW. In vivo and in vitro evidence for the involvement of tumor necrosis factor alpha in the induction of leptin by lipopolysaccharide. Endocrinology 1998; 139: 2278-83
41. Laye S, Gheusi G, Cremona S et al. Endogenous brain IL-l mediates LPS-induced anorexia and hypothalamic cytokine expression. Am J Physiol 2000; 279: R93-8
42. Laviano A, Cangiano C, Fava A, Muscaritoli M, Mulieri G, Fanelli FR. Peripherally injected IL-l induces anorexia and increases brain tryptophan concentrations. Adv Exp Med Biol 1999; 467: 105-8
43. McHugh KJ, Weingarten HP, Keenan C, Wallace JL, Collins SM. On the suppression of food intake in experimental models of colitis in the rat. Am J Physiol 1993; 264: R871-6
44. McHugh KJ, Collins SM, Weingarten HR Central interleukin-l receptors contribute to suppression of feeding after acute colitis in the rat. Am J Physiol 1994; 266: R1659-63
45. Ballinger A, El-Haj T, Perrett D et al. The role of medial hypothalamic serotonin in the suppression of feeding in a rat model of colitis. Gastroenterology 2000; 118: 544-53
46. Barbier M, Cherbut C, Aube AC, Blottiere HM, Galmiche JP. Elevated plasma leptin concentrations in early stages of experimental intestinal inflammation in rats. Gut 1998; 43: 783-90
47. Ballinger A, Kelly P, Hallyburton E, Besser R, Farthing M. Plasma leptin in chronic inflammatory bowel disease and HIV: Implications for the pathogenesis of anorexia and weight loss. Clin Sci (Colch) 1998; 94: 479-83
48. Hoppin AG, Kaplan LM, Zurakowski D, Leichtner A, Bousvaros A. Serum leptin in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1998; 26: 500-5
49. WiUiamson RC. Intestinal adaptation. N Engl J Med 1978; 298: 1393-02
50. Li E. Bacterial overgrowth. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of Gastroenterology. Philadelphia: J.B. Lippincott, 1995: 1673-80
51. Kanof ME, Lake AM, Bayless TM. Decreased height velocity in children and adolescents before the diagnosis of crohn's disease. Gastroenterology 1988; 95: 10-15
52. Markowitz J, Daum F. Growth impairment in pediatric inflammatory bowel disease. Am J Gastroenterol 1994; 89: 319-26
53. Kirschner BS. Growth and development in chronic inflammatory bowel disease. Acta Pediatr Scand 1990; 366(Suppl): 98-104
54. Ballinger AB, Camacho-Hubner C, Croft NM. Growth failure and intestinal inflammation. Q J Med 2001; 94: 121-5
55. Solomans NW, Rosenfield RL, Jacobs RA. Growth retardation and zinc deficiency. Pediatr Res 1976; 10: 923-7
56. Sturniolo GC, Molokhia MM, Shields R, et al . Zinc absorption in crohn's disease. Gut 1980; 21: 387-31
57. Nishi Y, Lifshitz F, Bayne MA et al. Zinc status and its relation to growth retardation in children with chronic inflammatory bowel disease. Am J Clin Nutr 1980; 33: 2613-21
58. Ballinger AB, Azooz O, El-Haj T, Poole S, Farthing MJG. Growth failure occurs through a decrease in insuHn-like growth factor 1 which is independent of undernutrition in a rat model of coHtis. Gut 2000; 46: 694-700
59. Beattie RM, Camacho-Hubner C, Wacharasindhu S, Cotterill AM, Walker-Smith JA, Savage MO. Responsiveness of IGF-1 and IGFBP-3 to therapeutic intervention in adolescents with crohn's disease. Clin Endocrinol 1998; 49: 483-9
60. Tenore A, Berman WF, Parks IS, Bongiovannie AM. Basal and stimulated GH concentrations in inflammatory bowel disease. J Clin Endocrinol Metab 1977; 44: 622-8
61. Braegger CP, Torresani T, Murch SH, Savage MO, Walker-Smith JA, MacDonald TT. Urinary growth hormone in growth-impaired children with chronic inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 49-52
62. De Benedetti F, Alonzi T, Moretta A et al. Interleukin-6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-1. J Clin Invest 1997; 99: 643-50
63. Siagel SA, Sheahy DJ, Nakada MX. The mouse human chimeric monoclonal antibody CA2 neutralizes TNF in vitro and protects transgenic mice from cachexia and TNF lethality in vivo. Cytokine 1995; 7: 15-25
64. Enomoto M, Pan HO, Kinoshita A, Yutani Y, Suzuki F, Takigawa M. Effects of tumor necrosis factor alpha on proliferation and expression of differentiated phenotypes in rabbit costal chondrocytes in culture. Calcif Tissue Int 1990; 47: 145-51
65. Wolf M, Bohm S, Brand M, Kreymann C. Pro-inflammatory cytokines interleukin 1 beta and tumor necrosis factor alpha inhibit growth hormone stimulation of insulin-like growth factor-1 synthesis and growth hormone receptor mRNA levels in cultured rat liver cells. Eur J Endocrinol 1996; 35: 729-37
66. Allen DB. Growth suppression by glucocorticoid therapy. Endocrinol Metabol Clin N Am 1996; 25: 699-717
67. Guistina A, Wehrenberg WB. The role of glucocorticoids in the regulation of growth hormone secretion-mechanisms and clinical significance. Trends Endocrinol Metab 1992; 3: 306-11
68. Untermann TG, Phillips LS. Glucocorticoid effects on somatomedins and somatomedin inhibitors. J Clin Endocrinol Metab 1985; 61: 618-26
69. Powell DW. Approach to the patient with diarrhea. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of Gastroenterology, 2nd edn. Philadelphia: J.B. Lippincott, 1995: 813-63
70. Kaunitz DK, Barrett KE, McRoberts JA. Electrolyte secretion and absorption: Small intestine and colon. In: Yamada T, Alpers DH, Owyang C, Powell DW, Silverstein FE, eds. Textbook of Gastroenterology, 2nd edn. Philadelphia: J.B. Lippincott, 1995: 326-61